Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sanofi Global Health

- PMLiVE

Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Dupixent is the first and only drug specifically recommended for EoE in the US

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

Sanofi launches new funding foundation

Foundation S is a philanthropic endowment fund aimed at encouraging healthier lives for future generations

- PMLiVE

Sanofi and McLaren Racing come together to maximise performance and operational excellence

The partnership will complement Sanofi’s R&D pipeline, which has 25 new launches planned over the next five years

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

Sanofi launches Diversity, Equity & Inclusion Board

The Board is the first of its kind in the pharma industry to have outside advisors

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis

The results were announced at the American Academy of Dermatology 2022 Annual Meeting

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links